Argen-X N.V. (Argenx). (4/26/17). "Press Release: Argenx Announces Results of Annual General Meeting 2017". Breda & Ghent.

	Organisation	Argen-X N.V. (Argenx) (Euronext + Nasdaq: ARGX)
	Today	Argenx SE (Euronext + Nasdaq: ARGX)
	Group	Argenx (Argen-X) (Group)
	Organisation 2	TR Advisory Services GmbH
	Product	investment banking
	Product 2	SIMPLE Antibody™ discovery platform
	Index term 2	Argenx–SEVERAL: investment, 201704–201705 US IPO $114.7m with 5.865m+879.75k ADSs at $17/ADS + new listing at Nasdaq
	Person	Rosenberg, A. A. (Tony) (TR Advisory Services GmbH 201704 before MPM Capital + Novartis Pharma)
	Person 2	Verhaeghe, Peter (Benaruca 200910)

argenx N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that all resolutions presented at the Company's Annual General Meeting were duly passed at the meeting, which was held today at 09:00 CEST.

Voting results

All proposed resolutions on the agenda for this annual meeting were approved. The results of the votes will be posted shortly on the Company's website and are summarized below:

> approval of the conversion of the Company into a Societas Europaea, a European legal entity, and the accompanying amendment of the articles of association;

> adoption of the Company's financial statements for the 2016 financial year; the 2016 financial statements and annual report are available on the Company's website; and

> appointment of Deloitte Accountants B.V. as external auditor for the 2017 financial year.

Changes to the board of directors

In the context of a further alignment of our governance model with international standards, Dr. J. de Koning, a non-executive director has resigned from the Board. Mr. Eric Castaldi also resigned as an executive director but remains the CFO of the Company. The shareholders have appointed Msc. A.A. Rosenberg as a new non-executive Director. Mr. Rosenberg served as Corporate Head of M&A and Licensing at Novartis Pharma from January 2013 until February 2015. He has also been a Managing Director of MPM Capital, a venture capital firm, since April 2015 and currently serves as CEO of TR Advisory Services GmbH, a consultancy firm advising on business development, licensing and mergers and acquisitions.

Peter Verhaeghe, chairman of the board, commented: "I would like to welcome Tony Rosenberg and to thank John de Koning for his long-lasting support to the company as venture capital investor and for his valuable strategic business and scientific contributions as a director. I am also pleased with the gradual transition of our board composition over the past years, with all non-executive directors qualifying now as independent directors.”

Authorization to use shares in relation to a possible NASDAQ listing

Furthermore, the shareholders’ meeting has granted the authorization to the board of directors to issue shares in relation to a possible NASDAQ listing of the Company in 2017.

About argenx

argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE Antibody™ Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies are designed to enable us to expand the therapeutic index of our product candidates.

www.argenx.com

For further information, please contact:

Joke Comijn, Corporate Communications Manager
+32 (0)477 77 29 44
+32 (0)9 310 34 19
info@arGEN-X.com

Beth DelGiacco (US IR)
Stern Investor Relations
+1 212 362 1200
beth@sternir.com

Forward-looking Statements

The contents of this announcement include statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes”, “estimates”, “anticipates”, “expects”, “intends”, “may”, “will”, or “should”, and include statements argenx makes concerning the intended results of its strategy, including its restructuring as a Societas Europaea and its possible NASDAQ listing in 2017. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx’s actual results may differ materially from those predicted by the forward-looking statements. argenx undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

Contact

argenx SE
Breda, The Netherlands
T +31 763 030 488
info@argenx.com

argenx BVBA
Zwijnaarde, Belgium
T +32 9 310 34 00

Record changed: 2023-06-05